Presumptive identification of Candida species other than C. albicans, C. krusei, and C. tropicalis with the chromogenic medium CHROMagar Candida

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Hospenthal, Duane R ^a   Beckius, Miriam L ^a   Floyd, Karon L ^a   Horvath, Lynn L ^a   Murray, Clinton K ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGENIC SUBSTRATE; AGAR; ANTIFUNGAL AGENT;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; COLOR; CONTROLLED STUDY; FUNGAL MORPHOLOGY; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; NONHUMAN; CLASSIFICATION; CULTURE MEDIUM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; VIRULENCE;

AGAR; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CULTURE MEDIA; MICROBIAL SENSITIVITY TESTS; VIRULENCE;

EID: 30544438360     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-1     Document Type: Article

References (23)

1. Trick WE, Fridkin SK, Edwards JR, Hejjeh RA, Gaynes RP, National Nosocomial Infections Surveillance System Hospitals: Secular trends of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.
2. Beck-Sague CM, Jarvis WR, NNIS System: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-1251.
3. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA, SENTRY participant group: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-3259.
4. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JE, Jarvis W, Dawson J, Wenzel RP, NEMIS Study Group: National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-258.
5. Hazen KC: New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462-478.
6. Kremery V, Barnes AJ: Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Infect Control 2002; 50: 243-260.
7. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN: In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis 2004; 48: 101-105.
8. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN, International Fungal Surveillance Participant Group: In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83.
9. Kirkpatrick WR, Revankar SG, McAtee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF: Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates. J Clin Microbiol 1998; 36: 3007-3012.
10. Odds FC, Davidson A: "Room temperature" use of CHROMagar Candida. Diagn Microbiol Infect Dis 2000; 38: 147-150.
11. Bernal S, Martin Mazuelos E, Garcia M, Aller AI, Martinez MA, Gutierrez MJ: Evaluation of CHROMagar Candida medium for the isolation and presumptive identification of species of Candida of clinical importance. Diagn Microbiol Infect Dis 1996; 24: 201-4.
12. Hospenthal DR, Murray CK, Beckius ML, Green JA, Dooley DP: Persistence of pigment production by yeast isolates grown on CHROMagar Candida medium. J Clin Microbiol 2002; 40: 4768-4770.
13. Huang LU, Chen CH, Chou CF, Lu JJ, Chi WM, Lee WH: A comparison of methods for yeast identification including CHROMagar Candida, Vitek system YBC and a traditional biochemical method. Zhonghua Yi Xue Za Zhi (Taipei) 2001; 64: 568-74.
14. Pfaller MA, Houston A, Coffmann S: Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol 1996; 34: 58-61.
15. Koehler AP, Chu K, Houang ETS, Cheng AFB: Simple, reliable, and cost-effective yeast identification scheme for the clinical laboratory. J Clin Microbiol 1999; 37: 422-426.
16. Odds FC, Bernaerts R: CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994; 32: 1923-1929.
17. Powell HL, Sand CA, Rennie RP: Evaluation of CHROMagar Candida for presumptive identification of clinically important Candida species. Diagn Microbiol Infect Dis 1998; 32: 201-204.
18. Murray CK, Beckius ML, Green JA, Hospenthal DR: Use of chromogenic medium in the isolation of yeasts from clinical specimens. J Med Microbiol 2005: 54: 981-985.
19. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE: Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
20. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN: In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-1071.
21. Hospenthal DR, Murray CK, Rinaldi MG: The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 2004; 48: 153-160.
22. Horvath LL, Hospenthal DR, Murray CK, Dooley DP: Direct isolation of Candida spp. from blood cultures on the chromogenic medium CHROMagar Candida. J Clin Microbiol 2003; 41: 2629-2632.
23. Colombo AL, Melo ASA, Rosas RFC, Salomao R, Briones M, Hollis RJ, Messer SA, Pfaller MA: Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis 2003; 46: 253-257.